US reports a record number of new coronavirus disease 2019 (COVID-19) cases; FDA reviewers endorse an Alzheimer disease drug; CDC director calls for asymptomatic testing strategy.
For the first time, the United States has reported 100,000 new coronavirus disease 2019 (COVID-19) cases in a single day, The New York Times reports. Ten months into the global pandemic, the new surge in cases has led to a shortage of N95 face masks at many health care facilities, despite increased production, according to The Wall Street Journal. Although the national supply of personal protective equipment (PPE) has improved since the spring, levels at some facilities remain below regulator-recommended levels. Because of the shortage, workers continue to ration and reuse masks, and state health departments warn that supplies may tighten further. In Michigan, almost two-thirds of health systems report less than a 3-week supply for 1 or more types of protective gear.
FDA clinical reviewers said that data showing that a new treatment for Alzheimer disease slowed cognitive decline were “exceptionally persuasive,” The Washington Post reports. The treatment, called aducanumab and developed by Biogen, appears to be safe and effective for treating patients with early-stage disease. Outside experts will now decide whether to recommend the agency approves the drug, making it the first new treatment for Alzheimer disease in nearly 2 decades. However, conflicting evidence on the drug’s effectiveness has led to controversy around the treatment, with one study concluding it was effective and another stating it showed little benefit. An FDA announcement on approval is expected by early March 2021.
CDC Director Robert Redfield, MD, stated that now is the time to develop a testing strategy for asymptomatic cases of COVID-19, CNN reports. CDC estimates show that 40% of individuals with COVID-19 show no symptoms. The announcement comes after a meeting with fellow White House Coronavirus Task Force member Deborah Birx, MD, and Utah Governor Gary Herbert to discuss mitigation efforts and testing in Utah. However, some experts feel the time to develop a testing strategy for this population has already passed. Currently, hospitalizations for COVID-19 are steeply rising in the Midwest, while nationwide, hospitalizations have increased 76% since September.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More